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Abstract: Acute ischemic stroke (AIS) due to thrombo-embolic occlusion in the cerebral 
vasculature is a major cause of morbidity and mortality in the United States and throughout 
the world. Although the prognosis is poor for many patients with AIS, a variety of 
strategies and devices are now available for achieving recanalization in patients with this 
disease. Here, we review the treatment options for cerebrovascular thromboembolic 
occlusion with a focus on the evolution of strategies and devices that are utilized for 
achieving endovascular clot extraction. In order to demonstrate the progression of this 
treatment strategy over the past decade, we will also present a single-center case series of 
AIS patients treated with endovascular thrombectomy. 
Keywords: acute ischemic stroke; endovascular; mechanical thrombectomy 
 
1. Introduction 
Stroke is the fourth leading cause of death in the United States and is also one of the leading causes 
of long-term disability [1,2–9]. Despite increased public awareness and widespread efforts to address 
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risk factors for this devastating disease, there are almost 800,000 new cases of stroke per year [2,10]. 
Ischemia is the most common underlying mechanism, accounting for 87% of all strokes [4,11].  
Prior to the use of thrombolytic agents in patients with acute ischemic stroke (AIS), treatment 
options were limited. Over the past two decades, AIS management has evolved tremendously, and 
there are now a variety of drugs and devices available. Here, we review the evolution of treatment 
modalities for AIS, beginning with a brief review of intravenous thrombolysis, followed by an in-depth 
look at endovascular techniques. We will focus on the evolution of strategies and devices that are 
utilized for achieving endovascular clot extraction. In order to demonstrate the progression of this 
treatment strategy over the past decade, we will also present a single-center case series of AIS patients 
treated with endovascular thrombectomy between January 2006 and December 2012.  
1.1. Intra-Venous Thrombolysis 
In 1996—based on the results of the National Institute of Neurological Disorders and Stroke 
(NINDS) rtPA Stroke Study Group trial [12,13]—the U.S. Food and Drug Administration (FDA) 
approved intravenous (IV) recombinant tissue plasminogen activator (rtPA) for the treatment of AIS. 
In the decade that followed, clinical data reaffirmed a clear benefit of IV rtPA in patients with  
AIS [10,12–21]. Nevertheless, it is estimated that only 1.8% to 2.1% of AIS patients receive IV 
thrombolysis (IVT) [10,22–24], which is at least partially attributable to the narrow three-hour time 
window for drug administration. Based on the results of the ECASS-3 trial published in 2008, the 
window of eligibility for IV rtPA was expanded to 4.5 h for a subset of AIS patients [19,25–31], and 
this is likely to increase the number of AIS patients able to be treated with IVT. However, even if time 
was not an exclusion criteria, only approximately 30% of AIS patients would be eligible for  
IV rtPA [32,33]. Furthermore, among the subset of patients who satisfy all eligibility criteria, only a 
minority of patients achieves an observable clinical benefit from treatment with IVT. More specifically, 
the NINDS trial of IV rtPA in AIS demonstrated only a 12% absolute increase in favorable functional 
outcomes (and showed no mortality benefit) in AIS patients treated with IV rtPA versus those treated 
with placebo [13,34,35]. In addition, due to its potent fibrinolytic effect, rtPA is associated with an 
increased risk of bleeding events, including systemic hemorrhage and intracerebral hemorrhage (ICH), 
and this risk outweighs the potential benefits of the drug beyond the 3- to 4.5-h window. In light of 
these limitations, alternative therapies have been devised for patients with AIS. There are a number of 
novel drugs in the translational pipeline or in clinical trials [1,3,5–9,36], but IV rtPA is currently the 
only FDA-approved fibrinolytic agent with an AIS indication.  
1.2. Intra-Arterial Fibrinolysis 
The intra-arterial administration of fibrinolytic agents obviates some of the limitations of the 
systemic intravenous route. The primary advantage of IA fibrinolysis (IAF) is the ability to administer 
the fibrinolytic agent directly into the occluded vessel, thereby maximizing the amount of drug that 
reaches the target vessels, while simultaneously minimizing systemic fibrinolysis. In this way, the risk 
of non-target hemorrhage may theoretically be reduced [10,37,38]. However, IAF procedures in 
general have some unique disadvantages, including increased time required for treatment initialization 
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and increased procedural complexity and costs, as well as an inherent risk of blood vessel injury 
associated with an endovascular procedure [10]. 
The safety and efficacy of IAF, using prourokinase (Pro-lyse) as the fibrinolytic agent, was 
demonstrated in the phase II Pro-lyse in Acute Cerebral Thromboembolism (PROACT-I) trial [4,39], 
as well as in the phase III PROACT-II trial [12]. In each of these trials, patients were randomized to 
either an experimental group (IA prourokinase plus low-dose IV heparin) or a control group (low-dose 
IV heparin alone), and treatment was administered within 6 h of symptom onset. Those patients who 
received IA prourokinase had significantly higher rates of recanalization and of a favorable functional 
outcome (defined as mRS ≤ 2) compared with controls. The rate of symptomatic ICH was higher in the 
experimental group than in the control group. Despite this, there was no difference in mortality 
between the groups. Although the rate of favorable functional outcome was higher in patients treated 
with IA prourokinase in the PROACT-II trial (40%) than in those patients treated with IV rtPA in the 
NINDS trial (31%), it is impossible to make any definitive statements regarding the relative efficacy of 
IVT and IAF, as there have not been any randomized controlled trials directly comparing the two. 
Furthermore, although the literature strongly suggests a higher recanalization rate in patients treated 
with IAF compared with those treated with IVT [12,14,16,18,20,21], there remains a significant 
proportion of AIS patients for whom fibrinolytic therapy alone, regardless of the route of delivery, is 
inadequate at recanalizing the occluded vessels. 
Early studies of AIS intervention showed that time to treatment is an important indicator of patient 
outcome [12]. Because of delays inherent in catheter-based intervention, attention turned to rapid 
administration of IV fibrinolytic therapy during transit to the angiography suite for endovascular 
intervention. The theoretical benefit of such a “bridging protocol” is that it preserves all of the 
advantages of IAF without the detraction of treatment delay as the resources for an endovascular 
procedure are mobilized. The Emergency Management of Stroke (EMS) Bridging Trial confirmed the 
feasibility of a combined IV and IA approach to fibrinolysis. This trial randomized AIS patients to 
either an experimental bridging protocol group (IVT followed by IAF) or a control group (IV-placebo 
followed by IAF) and demonstrated an increased rate of recanalization with the bridging protocol, but 
no difference in functional outcomes [23]. Bridging protocols have been further investigated in the 
Interventional Management of Stroke (IMS) studies, a series of three prospective trials of IAF in 
patients with persistent occlusion following IV rtPA treatment [27,28,30]. Patients enrolled in IMS-I 
and -II had significantly better functional outcomes than placebo-treated patients from the NINDS trial 
and marginally better outcomes when compared to NINDS patients who received IV rtPA. However, 
the recently published IMS-III trial demonstrated no improvement in outcomes in patients treated with 
endovascular modalities following IVT (as will be discussed below) [40]. 
PROACT-II demonstrated the benefit of IAF by administration of pro-urokinase at the proximal 
margin of the occlusive thromboembolus alone. An additional advantage of the intra-arterial route of 
fibrinolytic administration is that it allows for direct manipulation of the occluding thrombus. 
Mechanical clot disruption is most easily achieved by repeatedly passing the endovascular guidewire 
across the site of obstruction, thereby macerating the clot and increasing the surface area upon which 
the fibrinolytic agent can have its effect. A number of novel strategies and devices have been 
developed to facilitate this process of mechanical clot disruption. For instance, continuous transcranial 
Doppler ultrasound has been utilized to direct ultrasonic energy towards the occluded vessel and a 
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sonographically-activated microcatheter—the EKOS micro-infusion catheter—has been developed to 
focus ultrasonic energy into the immediate vicinity of the occlusion. In order to evaluate the efficacy 
of mechanical clot disruption as an adjunct to IAF, a subset of IMS-II patients were treated with an 
EKOS Primo Micro-Infusion Catheter at the time of IAF administration. Although patients treated 
with the sonographically-activated EKOS catheter had a numerically higher rate of recanalization as 
compared with a similar cohort of patients who received IAF alone, this difference did not reach 
statistical significance [26]. Laser thrombolysis instruments have also been developed, including the 
LaTIS (Spectanetics, Colorado Springs, CO) and Endovascular Photo-Acoustic Recanalization (EPAR, 
Endovasix, Belmont, CA), but trials of these devices have not demonstrated a definitive clinical 
benefit [10,22].  
Balloon angioplasty has been used to treat coronary and other peripheral arterial occlusions for 
many years. Similarly, a thromboembolic occlusion of a cerebral artery can be directly manipulated 
using balloon angioplasty. Although angioplasty has long been used non-acutely in patients with 
cerebral vascular stenosis [25], the first reports of using this technique in the setting of acute stroke are 
relatively more recent [32]. Nevertheless, angioplasty for the treatment of AIS has been shown to be a 
safe strategy with high rates of recanalization [34,35]. Therefore, angioplasty has become an 
increasingly common technique in multimodal endovascular approaches to patients with AIS, 
particularly those patients with refractory vessel occlusion following multiple treatment attempts. The 
intention of angioplasty is to radially displace or fragment the occlusive thrombus towards the 
periphery of the blood vessel, thereby reestablishing blood flow through the site of occlusion. 
Similarly, stent deployment, either alone or in conjunction with balloon angioplasty, has been shown 
to be a highly effective means of achieving flow restoration in patients with AIS. In a meta-analysis of 
studies in which patients received cerebrovascular stents for the treatment of AIS, successful 
recanalization was achieved in 113 of 127 patients (89%), while hemorrhagic complications occurred 
in 26 patients (20.5%), 12 (9.4%) of which were symptomatic [41]. In the only prospective trial 
included in this meta-analysis—the SARIS Trial [36]—successful recanalization was achieved in 
100% of the 20 enrolled patients using the Wingspan Stent (Boston Scientific, Natick, MA), with only 
one (5%) symptomatic and two (10%) asymptomatic ICHs. More recently, 105 patients with AIS who 
were either ineligible for or failed to respond to IV rtPA were assigned to receive either balloon 
angioplasty with stent placement or no further treatment [42]. Those patients who underwent balloon 
angioplasty with stent placement had significantly higher rates of recanalization and favorable 
functional outcome (mRS ≤ 2). Although the rate of recanalization seems to be higher with stenting 
than with alternative endovascular therapies for AIS, with a similar rate of procedure-related 
complications, the use of stents in patients with AIS has been limited by concerns about the need for 
dual anti-platelet therapy, the increased risk of hemorrhage and possible in-stent stenosis. 
1.3. Endovascular Thrombectomy 
In contrast to IVT or IAF, in which fibrinolytic agents are utilized to expedite the process of clot 
dissolution, endovascular thrombectomy aims to extract the clot from the occluded vessel. There are a 
number of advantages of mechanical thrombectomy, including rapid flow restoration, a decreased risk 
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Merci device within 8 h of AIS symptom onset. Successful recanalization was achieved in 12 (43%) of 
these patients when the Merci device was used alone and in 18 (64%) patients when adjunctive IA 
rtPA was administered. There was one procedure-related complication (unintended detachment of the 
tip of the Merci retriever) that was rectified without clinical consequence and 12 ICHs, all of which 
were asymptomatic. In the similarly designed phase II trial, recanalization was achieved in 68/141 
(48%) patients and in 85 patients (60%) when adjunctive rtPA was used. Clinically significant 
procedural-related complications occurred in 10 patients (7.1%), and symptomatic ICH occurred in  
11 patients (7.8%). There was no difference in the rate of hemorrhage between those patients who 
were treated with the Merci device alone versus those treated with adjuvant IAF. This trial confirmed 
the safety and efficacy of the Merci retriever for mechanical thrombectomy in AIS, leading to the 2004 
FDA-approval of this device for patients who fail or are ineligible for IV rtPA. 
An additional multi-center, prospective, single-arm trial of mechanical thrombectomy with the 
Merci retriever device—The Multi-MERCI trial [13,44]—was similar to the phase I and II trials 
described above with the notable exception that patients with persistent large vessel occlusion after IV 
rtPA treatment were eligible for inclusion. In addition, the Multi-MERCI trial utilized the newer 
second-generation Merci devices, in contrast to the phase I and II trials discussed above, in which the 
first-generation devices were used. Published in 2008, this trial demonstrated successful recanalization 
in 75/131 patients (57.3%), with clinically significant procedure-related complications occurring in  
nine patients (5.5%) and symptomatic ICH occurring in 16 patients (9.8%). Furthermore, the rate of 
successful recanalization increased to 69.5% (91/131 patients) following adjunctive treatment with IA 
rtPA and/or additional attempts at clot extraction using the older-generation Merci devices. 
Importantly, despite the inclusion of patients who had received IV rtPA prior to endovascular 
intervention, there was no significant increase in the rate of ICH or procedural-related complications as 
compared with the phase I- and II trials described above, therefore suggesting that the Merci retrieval 
device may be safely utilized in AIS patients with persistent occlusion after IV rtPA.  
A number of other distally deployed devices have been developed and successfully utilized to 
perform mechanical thrombectomy in patients with AIS, including the Neuronet device (Guidant, Santa 
Clara, CA) [10,13,15,17,19,45], the Catch thrombectomy device (Balt, Montmorency, France) [24,46], 
the Phenox Clot Retriever (Phenox, Bochum, Germany) [19,29,31,47], the Attracter-18 device (Target 
Therapeutics, Fremont, CA) [48] and the Alligator Retrieval Device [49,50]. However, the safety and 
efficacy of these devices has not been firmly established in large prospective trials, as in the case of the 
Merci devices, and therefore, the Merci retriever remains the only distally deployed device with FDA 
approval for use in AIS patients. 
1.3.2. Proximally Deployed Devices 
With proximally deployed devices, the clot is grasped or aspirated from the proximal vasculature. 
The Penumbra Thromboaspiration System (Penumbra, Alameda, CA) is the most widely used and the 
only such device with FDA approval for use in AIS patients. The Penumbra System consists of two 
components: a reperfusion microcatheter attached to a suction pump and a separator, which is a  
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patients who had received IV t-PA to further endovascular treatment or to no additional intervention. 
This trial was terminated on the basis of futility of further endovascular intervention after 656 of the 
planned 900 participants had been enrolled [40]. Importantly, in both of these trials, the time to 
intervention was longer in the IA arm than in the IVT arm, which may have contributed to the lack of 
superior clinical benefit of an endovascular approach. Although subgroup analyses of these trials 
suggested that the lack of clinical benefit was not due to endovascular treatment delays, future trials 
should strive to minimize this discrepancy in time to treatment. 
The MR RESCUE Trial assessed the utility of pretreatment neuroimaging (either CT or MRI) for 
identifying patients with a favorable penumbral pattern who are most likely to benefit from 
endovascular intervention, either as the initial treatment or after failed recanalization with IV tPA 
(provided that pretreatment neuroimaging demonstrated substantial salvageable tissue). The results 
failed to demonstrate that pretreatment brain imaging allowed for identification of patients who would 
differentially benefit from further endovascular intervention. In addition, similar to the SYNTHESIS 
Expansion and IMS-III trials described above, the MR RESCUE Trial failed to demonstrate superiority 
of endovascular intervention over standard medical therapy with IV tPA [61]. 
2. Methods 
This case series includes all patients who underwent endovascular mechanical thrombectomy for 
AIS between January 2006 and December 2012 at Columbia University Medical Center. Monthly case 
logs were obtained from the Department of Neurosurgery, and all patients with AIS were identified 
using International Classification of Diseases, Clinical Modification, 9th Revision (ICD-9) primary 
diagnosis codes 433–434.91. Among all patients with AIS as identified by ICD-9 codes, those patients 
who were treated via endovascular intervention (endovascular thrombolysis, mechanical thrombectomy 
or angioplasty/stenting) were identified using current procedural terminology (CPT) codes. Patients 
with venous sinus thromboses were excluded, as were patients who were undergoing non-acute 
intervention for recurrent transient ischemic symptoms. 
For each patient who underwent mechanical thrombectomy, medical records were retrospectively 
reviewed, including demographic, admission, laboratory, imaging, procedural, discharge and  
follow-up data. Pre-procedural National Institute of Health Stroke Scale (NIHSS) scores were obtained 
from the admission exam documentation. The degree of post-procedural recanalization was classified 
as “incomplete”, “partial” or “complete/nearly complete” based on the thrombolysis in cerebral 
infarction (TICI) score (Table 1). The TICI score was either reported by the attending physician in the 
procedural note or else determined by retrospective review of intra-operative angiographic images. 
Information regarding procedural complications—including vessel dissection or rupture, groin 
hematoma, device malfunction or clot embolization to a previously non-occluded vessel—was 
obtained from the procedural notes. All imaging scans obtained following the procedure were 
reviewed in order to identify post-procedural hemorrhages, and for those patients who were found to 
have radiographic evidence of hemorrhage, progress notes were reviewed to further classify these as 
symptomatic (i.e., coinciding with a deterioration in neurological exam) or asymptomatic (i.e., no 
deterioration in neurological exam coincident with the radiographic finding of hemorrhage). The 
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documented discharge exam was used to calculate discharge mRS for each patient: “good outcome” 
was defined as mRS ≤ 2.  
Table 1. Description of thrombolysis in cerebral infarction (TICI) score and corresponding 
degree of recanalization used in this case series. 
Score TICI Recanalization Degree of Recanalization 
0 No perfusion distal to the occlusion 
Incomplete 
1 
Perfusion past the site of occlusion, but no 
significant distal branch filling 
2a Incomplete (<50%) distal branch filling Partial 
2b Incomplete (>50%) distal branch filling 
Complete or nearly complete 
3 Full perfusion with filling of all distal branches 
3. Results 
A total of 128 patients were identified with ICD-9 codes consistent with AIS, as well as CPT codes 
consistent with an endovascular intervention. After reviewing the medical records, four patients were 
excluded, due to primary diagnoses of venous sinus thrombosis, and seven patients were excluded, due 
to the fact that the indication for endovascular intervention was recurrent chronic ischemic symptoms, 
rather than AIS. Among the remaining 117 patients, 84 underwent mechanical thrombectomy, either 
alone or as part of a multi-modal endovascular approach (i.e., in conjunction with IAF and/or 
angioplasty/stenting), and 33 patients underwent primary IAF. 
3.1. Pre-Procedural Data 
Of the 84 patients who underwent mechanical thrombectomy and were included in the analysis, the 
average age was 64.2 (SD 16.7). Seventy-four patients (88.1%) had anterior circulation occlusions, and 
10 patients (11.9%) had occlusions in the posterior circulation. More specifically, the occlusion was in 
the internal carotid artery (ICA) in 29/84 patients (34.5%), in the middle cerebral artery (MCA) in 
43/84 (51.2%), in the anterior cerebral artery (ACA) in 1/84 (1.2%), in the vertebral artery in 2/84 
(2.4%) and in the basilar artery in 9/84 (10.7%). Forty-nine of the 84 patients (58.3%) had occlusions 
in the left-side circulation and 25/84 (29.8%) had occlusions in the right-side circulation. 
Thirty-one of the 84 patients (36.9%) received IV rtPA prior to endovascular intervention, and the 
average time between symptom onset (and time of last known normal) and IV rtPA administration was 
120 min (standard deviation [SD] 38.4 min). The average pre-operative National Institute of Health 
Stroke Scale (NIHSS) score among all patients who underwent mechanical thrombectomy was  
19.7 (SD 6.8). Among patients who received IV rtPA prior to mechanical thrombectomy, the average  
pre-operative NIHSS score was 19.2 (SD 5.2), versus 20.0 (SD 7.7) in those who did not receive  
IV rtPA.  
3.2. Procedural Data 
Sixteen patients (18.8%) were treated with a distally deployed device (15 with the Merci Retriever 
and one with the Attractor-18), 64 (75.3%) were treated with a proximally deployed device (the 
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Penumbra Thromboaspiration System in all cases) and 11 (12.9%) were treated with an intra-clot 
deployed device (10 with the Solitaire Stentriever and one with the Trevo Retriever). In seven of the 
16 cases in which the distally deployed device was used, it was done so only after a failed attempt at 
recanalization using the Penumbra aspiration system. Twenty-eight of 84 patients (33.3%) received 
IA-rtPA in addition to mechanical thrombectomy, including 3/9 (33.3%) of those treated with a 
distally deployed device, 20/57 (35.1%) of those treated with a proximally deployed device and  
5/11 (45.5%) of those treated with an intra-clot deployed device. None of the seven patients treated 
with both distally and proximally deployed devices received IAF. Of the 28 patients who received IAF, 
12 also received IV rtPA prior to endovascular intervention. In addition, 6/84 patients (7.1%) received 
balloon angioplasty, and intravascular stents were placed in four of these cases. For a graphic depiction 
of the proportion of AIS patients who were treated with each of the different endovascular modalities 
during each of the seven years of this case series, see Figure 4. 
Figure 4. Endovascular treatment modalities used by year (as a percentage of all 
endovascular interventions for acute ischemic stroke (AIS)). 
 
The average procedure duration for all patients who underwent mechanical thrombectomy was  
154 min (SD 56): 180 min (SD 30) when a distally deployed device was used, 150 min (SD 62) with 
proximally deployed devices, 162 min (SD 45) with intra-clot deployed devices and 168 min (SD 57) 
with combined distally and proximally deployed devices. Among those patients who underwent 
mechanical thrombectomy with adjunctive IAF, the average procedure duration was 169 min (SD 44), 
versus 149 min (SD 60) among those who did not receive adjunctive IAF. 
Complete or nearly complete recanalization (TICI 2b or 3) was achieved in 40.5% of all patients 
who underwent mechanical thrombectomy. When a distally deployed device was used alone, the rate 
of complete or nearly complete recanalization was 0.0%, while 40.4% of patients achieved this degree 
of recanalization with a proximally deployed device, 81.8% with an intra-clot deployed device and 
28.6% with combined distally and proximally deployed devices (Table 2). In addition, the rate of 
complete or nearly complete recanalization was 42.9% among those patients who received IA-rtPA 
and 40.4% among those who did not.   
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Table 2. Degree of recanalization stratified by type of device used. 
Degree of Recanalization Number Percentage 
Distally deployed device (n = 9) 
Incomplete 5/9 55.6% 
Partial 4/9 44.4% 
Complete/nearly complete 0/9 0.0% 
Proximally deployed device (n = 57) 
Incomplete 18/57 31.6% 
Partial 16/57 28.1% 
Complete/nearly complete 23/57 40.4% 
Combined proximally & distally deployed devices (n = 7) 
Incomplete 3/7 42.9% 
Partial 2/7 28.6% 
Complete/nearly complete 2/7 28.6% 
Intra-clot deployed device (n = 11) 
Incomplete 2/11 18.2% 
Partial 0/11 0.0% 
Complete/nearly complete 9/11 81.8% 
Procedure-related complications occurred in 6 patients (7.1%), including four intra-operative 
hemorrhages (one of which was caused by vessel rupture), one groin hematoma and one device 
malfunction. In three of the four cases complicated by intra-operative hemorrhage (including the one 
complicated by vessel rupture), a proximally deployed device was used, while a distally deployed 
device was utilized in the fourth case. The device malfunction involved an unintended detachment of a 
Solitaire stentriever device tip, which was left in situ without clinical consequence. In addition, clot 
fragmentation and distal embolization occurred in 10/84 (11.9%) cases, (2/9 cases with distally 
deployed devices, 7/57 cases with proximally deployed devices and 1/11 cases utilizing an intra-clot 
deployed device), although this resulted in occlusion of a previously non-occluded vessel in only  
3 cases. 
3.3. Post-Procedural Data 
Reperfusion hemorrhage was noted on post-procedural radiographic imaging in 44/84 patients 
(52.4%), and 13 (15.5%) of these were symptomatic, (Table 3). A good outcome (mRS ≤ 2) was 
observed in 14/84 patients (16.7%), while in hospital mortality occurred in 25/84 patients (29.8%), 
(Table 4). 
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Table 3. Rate of reperfusion hemorrhage (total and symptomatic) stratified by type of 
device used and by adjunctive administration of fibrinolytic therapy. IVT, IV thrombolysis; 






Total 44/84 52.4% 13/84 15.5% 
With IVT 18/31 58.1% 7/31 22.6% 
Without IVT 26/53 49.1% 6/53 11.3% 
With IAF 14/27 51.9% 5/27 18.5% 
Without IAF 30/57 52.6% 8/57 14.0% 
Distally deployed device 5/9 55.6% 1/9 11.1% 
Proximally deployed device 29/57 50.9% 9/57 15.8% 
Combined proximally and 




Intra-clot deployed device 7/11 63.6% 2/11 18.2% 
Table 4. Functional outcome stratified by type of device used and by adjunctive administration 
of fibrinolytic therapy. 
Good Outcome  
(mRS ≤ 2) 
Death  
(mRS = 6) 
Total 14/84 16.7% 25/84 29.8% 
With IVT 3/31 9.7% 10/31 32.3% 
Without IVT 11/53 20.8% 15/53 28.3% 
With IAF 7/27 25.9% 8/27 29.6% 
Without IAF 7/57 12.3% 17/57 29.8% 
Distally deployed device 1/9 11.1% 2/9 22.2% 
Proximally deployed device 8/57 14.0% 18/57 31.6% 
Combined proximally and distally 
deployed devices 1/7 14.3% 2/7 28.6% 
Intra-clot deployed device 4/11 36.4% 3/11 27.3% 
4. Discussion 
As demonstrated by this case series, there are a multitude of different strategies and devices 
available for the endovascular management of AIS, and the patterns of AIS management have been 
continuously changing over the past decade. In 2006 and 2007, a majority of AIS patients who 
underwent endovascular intervention at our institution were treated with IAF. Furthermore, greater 
than 50% of these patients did not undergo mechanical thrombectomy as an adjunct to IAF, despite the 
fact that the Merci retriever was FDA approved for use in this population. This practice pattern may be 
a reflection of the available data at the time, which suggested that the rates of recanalization and of 
favorable functional outcome were not significantly different in patients treated with IAF versus those 
treated with the Merci retriever [4,12,39,43]. In those patients in which mechanical thrombectomy was 


















































g in 2008, 
o were tre
 the litera






























































. In fact, b
at our instit








































r shift in 
bectomy.
sed previou
































































































Brain Sci. 2013, 3 535 
 
from this case series that practice patterns are largely driven by the contemporary literature regarding 
the relative efficacy of the available strategies and devices. 
As this dynamic and growing field continues to develop, there will undoubtedly be a plethora of 
new devices and strategies that become available. As such, there will be a continual need for 
investigation and re-evaluation in order to establish current evidence-based practice guidelines.  
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